Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Zackary Gangwer

Podiatrist, Foot & Ankle Surgery Norfolk, NE Doctor of Podiatric Medicine

NPI 1962768325 CMS profile 1355899

2701 W Norfolk Ave, Norfolk, NE 68701

Open in the dashboard

General payments

$66,466

425 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Zackary Gangwer of Norfolk, NE is reported in the CMS Open Payments database as having received $66,466 across 425 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,900 49
2024 General $8,957 65
2023 General $8,377 65
2022 General $14,142 83
2021 General $12,087 71
2020 General $5,878 30
2019 General $11,125 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zackary Gangwer
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Zackary Gangwer were reported at $5,900. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Zackary Gangwer Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $11,125 $389 $118–$1,406 $163
2020 $5,878 $191 $62–$691 $114
2021 $12,087 $329 $104–$1,341 $132
2022 $14,142 $419 $125–$1,611 $149
2023 $8,377 $377 $128–$1,164 $160
2024 $8,957 $394 $134–$1,168 $164
2025 $5,900 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $19,732 175 payments
  2. Arthrex, Inc. $13,641 77 payments
  3. Crossroads Extremity Systems, LLC $8,237 13 payments
  4. Medical Device Business Services, Inc. $3,864 3 payments
  5. Conetic Solutions, Inc. $3,653 38 payments
  6. OSSIO Inc. $3,229 7 payments
  7. Medline Industries, Inc. $2,701 20 payments
  8. Zimmer Biomet Holdings, Inc. $2,430 25 payments
  9. International Life Sciences $2,160 4 payments
  10. Vilex in Tennessee, Inc. $1,568 10 payments
  11. Other $5,253 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $25,471 75 payments
  2. Food and Beverage $18,182 332 payments
  3. Consulting Fee $14,225 10 payments
  4. Education $8,589 8 payments
Products named General payments · program years 2019–2025
  1. MEDLINE UNITE $2,791 24 payments
  2. Medical Implant $2,737 5 payments
  3. INFINITY $2,385 22 payments
  4. PROSTEP $2,327 14 payments
  5. PROPHECY $2,258 18 payments
  6. ORTHOLOC 2 LAPIFUSE $2,218 25 payments
  7. INBONE $2,047 8 payments
  8. ORTHOLOC 3DI $1,924 6 payments
  9. VARIAX $1,866 7 payments
  10. AUGMENT INJECTABLE $1,749 23 payments
  11. Other $20,000 193 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

241

Median for Podiatry: 160

Drug cost

$1,885

Median for Podiatry: $2,368

Branded share of claims

14.5%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 92 $679
Ondansetron Odt Ondansetron Brand 35 $403
Pregabalin Generic 16 $282
Oxycodone Hcl Generic 44 $217
Terbinafine Hcl Generic 22 $176
Cyclobenzaprine Hcl Generic 32 $129

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$67,081

Medicare's payments for the services billed

Medicare patients

246

Average age 74

Services billed

917

151 women, 95 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Diabetes 26%
Ischemic heart disease 22%
Osteoporosis 20%
Chronic kidney disease 19%
Atrial fibrillation 18%
Depression 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

425 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record